Previous close | 331.00 |
Open | 330.40 |
Bid | 328.10 x N/A |
Ask | 328.30 x N/A |
Day's range | 326.10 - 330.42 |
52-week range | 306.80 - 350.50 |
Volume | |
Avg. volume | 26,086,705 |
Market cap | 29.974B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 29.84 |
EPS (TTM) | 0.11 |
Earnings date | 01 Aug 2024 - 15 Aug 2024 |
Forward dividend & yield | 0.06 (1.77%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | 363.53 |
Consumer healthcare company Haleon reported first-quarter revenue slightly below market estimates on Wednesday, as volumes declined due to retailer destocking in U.S. and cooling demand for some of its medicines after a surge last year. The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth.
The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth. On a reported basis, revenue was down 2.2% on last year.
The consumer healthcare group is aiming to close the site on a phased basis over the next two years.